BPMX Stock Soars 30% on Positive Trial Results for BPX-04

BPMX stock

Small biotech company BioPharmX Corp (NYSE:BPMX) has been on a tear in Tuesday’s trading session, and BPMX stock rose by as much as 30% on the back of highly positive news about its topical minocycline gel BPX-04.

Highly Positive Results

According to the announcement made today, BioPharmX received highly positive results from the Phase 2b trial of its product, BPX-04. BPX-04 is meant for the treatment of papulopustular rosacea, which is a form of skin disorder. The important fact about the results from the trial is that the product met both the endpoints that were necessary for terming it a success. There was a marked improvement in the condition of the patients, and after a 12-week trial, many of the patients had almost clear skin. A phase 3 study is going to take place soon.

The Phase 2B trial was extremely thorough in nature as BioPharmX enrolled as many as 206 subjects with the minimum age of 18 years. The trial was not only randomized and double lined but also vehicle controlled, which lends it a lot of credence. The entire trial was conducted across a total of 11 locations across the United States, and the final results were positive.

Enter Your E-mail Address To Subscribe

* indicates required
 

>> Genfit Stock Showcases Elafibranor Opportunity On the Recent Lull

BPMX stock is now trading at $1.14, higher by about 30%.

 The clinical trial not only looked at the effectiveness of the gel but also at the safety aspect when patients are using it once every day. The condition of papulopustular rosacea generally leads to the inflammation of the face, and the study tried to find whether any statistically significant improvement took place in the patients after the 12-week treatment had been completed.

Dr. Mark Amster, who is a dermatologist and an investigator in this trial, stated that the patients who had participated in the trial were happy to have taken part. He went to highlight the ‘impressive efficacy’ of the gel BPX-O4 as well. Investors will, no doubt, be looking forward to the results from the next phase of the trial.

Despite today’s rally, BPMX stock is still down 60% since the beginning of this year and 85% from its 52-week high of $6.75.

>> Read More Biotech News

Featured image: DepositPhotos © Alex011973